Global Cannabis Valuation: Liquidity Still Sets the Price
Cannabis equities remain a global valuation market in name but a collection of sharply different liquidity regimes in practice. Monday’s tape made that distinction unusually clear: RWB.CN gained 33.33% on volume of 646,562, MEM.AX advanced 20.00% on volume of 100,000, and GNLN rose 15.50% on volume of 79,701. At the same time, WTER fell 44.29%, HEPA declined 26.67%, and Canadian-listed CANN and POSAF each fell roughly 11%.
The thesis is straightforward: cannabis valuation is currently less a function of broad sector classification than of whether an issuer can demonstrate durable cash economics, finance its operations without disproportionate dilution, and trade in a venue where incremental capital has a credible path to participate. That is a tougher standard than reporting adjusted EBITDA growth. It is also why the global opportunity set needs to be segmented by jurisdiction, listing venue, capital structure and cash-flow evidence—not merely by cannabis exposure.
For investors assessing the group across North America, Europe and APAC, the key distinction is between a trading move and a valuation signal. A large percentage move in a thin or distressed security can alter sentiment, but it does not automatically establish a higher fundamental value. Conversely, a modestly moving listed operator with evidence of financial self-sufficiency can matter more to long-duration exposure than a headline-grabbing single-session spike.
The filing-led valuation test: EBITDA is not yet equity cash flow
The most complete current filing record in the package remains TLRY, which is useful as a sector diagnostic even where it is not the central trading focus. In the company’s fiscal 2026 earnings release, Tilray reported $915.454 million of net revenue and $61.139 million of adjusted EBITDA, while free cash flow was negative $98.624 million. Management guided to fiscal 2027 adjusted EBITDA of $68 million to $75 million and stated that it expects annual revenue above $1 billion.
Those figures frame a valuation issue that applies well beyond Tilray: adjusted EBITDA can establish operating progress, but it cannot on its own settle the equity-value question when cash consumption remains material. The relevant filing is Tilray’s fiscal 2026 earnings release filed as SEC Exhibit 99.1, and its implications are broader than one company. In cannabis, reported growth, adjusted profitability and equity returns can separate when working capital, capital expenditure, acquisition costs, interest burden or dilution absorb operating gains.
The balance-sheet evidence reinforces that point. At the fiscal year-end, Tilray reported $225.977 million of cash and cash equivalents, $5.289 million of marketable securities, $138.585 million of current and long-term debt, and $79.529 million of convertible debentures. Shares issued and outstanding were 131,683,075, compared with 106,067,875 a year earlier after retrospective adjustment for the reverse split. The same SEC Exhibit 99.1 filing therefore provides both sides of the valuation debate: liquidity and operating scale on one side; negative free cash flow and per-share dilution risk on the other.
That is the proper framework for global cannabis valuation. Investors should resist treating revenue scale as synonymous with shareholder value creation until the issuer supplies a credible bridge from adjusted EBITDA to free cash flow, and from corporate growth to per-share cash-flow capacity.
Why this matters across Canadian, European and APAC listings
Canadian and OTC cannabis securities remain particularly exposed to the difference between a sharp market move and investable liquidity. RWB.CN rose 33.33% to $0.04, yet CIN continues to classify the issuer as distressed. That combination is not contradictory. It is precisely why percentage moves require context: distressed issuers can react violently to limited flow, while the underlying valuation still depends on solvency, capital structure and a durable operating path.
The same caution applies to CANN, which fell 11.11% to $0.02, and POSAF, down 11.09% to $0.05. Neither move establishes a sector-wide conclusion. It does, however, show that the Canada-and-OTC complex is still prone to abrupt repricing in securities where liquidity can dominate fundamental information in the short run. PCLO, which gained 9.09% to $0.06, offers the reciprocal lesson: a positive session can restore attention, but the market still needs reporting evidence before converting attention into an enduring multiple.
Europe presents a different version of the same valuation problem. Germany-facing cannabis names can be associated with a more internationally oriented medical and regulated-market narrative, but local listing liquidity remains decisive. SANT.DE gained 1.80% to $1.02, while B8F.DE gained 1.10%. Yet CIN continues to maintain SynBiotic on its distressed list. A listed European issuer can benefit from a jurisdictional narrative while still being subject to financing constraints and limited market depth. The relevant question is not whether Europe has strategic appeal; it is whether the public issuer can translate that appeal into recurring, disclosed cash generation.
APAC’s tape underscores the same point from another direction. MEM.AX advanced 20.00% to $0.01, while ATC.AX rose 100.00% on volume of 2,089,081. These moves are meaningful for risk appetite and local trading conditions, but they should not be conflated with a universally comparable operating re-rating. ASX-listed cannabinoid-adjacent equities can offer differentiated exposure to innovation, life sciences and ancillary themes, yet their valuation requires the same discipline applied to Canadian and European names: assess liquidity, the relevance of the underlying business model, funding needs and the evidence supporting future cash flow.
Macro matters, but the package does not support a macro call
No macro data are available in today’s facts package. That limits any definitive call on rates, the U.S. dollar or broad risk appetite. Still, the absence of a verified macro print does not remove macro sensitivity from cannabis valuation; it simply means it should not be quantified here.
The differentiated transmission mechanism is clear. A stronger global appetite for risk can lift thinly traded Canadian, European and APAC listings quickly because incremental capital can have an outsized impact on quoted prices. But that same liquidity characteristic can reverse abruptly. By contrast, companies with larger revenue platforms and deeper disclosure records may be assessed more directly on cash conversion and balance-sheet execution.
For North American issuers, U.S. policy remains an important optionality variable, but it should not be capitalized as certainty. The DEA’s order on transcript corrections and post-hearing briefs states that hearings occurred from June 29 through July 15, 2026, with proposed transcript corrections and post-hearing briefs due August 17, 2026. Subsequent decision timing was not established in the source material.
That matters globally because a U.S. regulatory change would likely influence sentiment across Canadian LPs, European medical-cannabis names and international platforms—not only direct U.S. operators. But a policy catalyst is not a substitute for issuer-level valuation support. The appropriate stance is to treat rescheduling as optionality, not as base-case cash flow.
The beverage-platform read-through is strategically global, financially unproven
Tilray’s international strategy illustrates the distinction between strategic relevance and valuation proof. Its filings describe BrewDog as a fiscal 2026 acquisition supporting a pro forma global beverage platform of approximately $500 million. An earlier release described an acquisition price of approximately £40 million in cash and a Carlsberg partnership beginning in 2027. The company’s earlier SEC-filed earnings release is important because it establishes a real global-platform rationale rather than a purely domestic cannabis narrative.
Yet the valuation issue remains execution. A diversified platform can broaden revenue sources and create distribution options, but investors need disclosed evidence that integration improves profitability and cash flow rather than merely expanding reported scale. Tilray’s fiscal 2026 Form 10-K also identifies significant competition in cannabis and beverage markets, including illicit-market participants and large, well-capitalized competitors. That is a reminder that geographic diversification does not eliminate competitive intensity.
For European issuers such as SANT.DE and B8F.DE, and APAC-adjacent names such as MEM.AX, the read-through is constructive only at the thematic level: global regulated-market development can expand investor attention. It does not eliminate the need for jurisdiction-specific execution, transparent reporting and disciplined capitalization.
What we’d watch
The primary watch item is evidence that adjusted EBITDA growth becomes free-cash-flow improvement without a disproportionate increase in the share count. Tilray’s $68 million to $75 million fiscal 2027 adjusted EBITDA guidance provides a concrete sector marker, but the more important question is whether reported operating progress begins to reduce cash consumption.
Second, watch whether Canadian and OTC volatility broadens into sustained volume and issuer-specific disclosure. RWB.CN’s 33.33% gain is a sentiment event, not yet a valuation verdict; CANN and POSAF demonstrate the opposite side of the liquidity equation.
Third, watch relative performance between Europe and APAC. SANT.DE, B8F.DE, MEM.AX and ATC.AX show that global cannabis-adjacent capital is not confined to North America. But a durable rerating requires more than localized price momentum: it requires financing resilience and cash-flow credibility.
Bottom line
Global cannabis valuation remains a cash-conversion and liquidity story first, with policy optionality and regional growth narratives layered on top. The sharp moves in RWB.CN, CANN, POSAF, SANT.DE, B8F.DE, MEM.AX and ATC.AX confirm that capital is still moving across Canada, Europe and APAC—but not evenly, and not always on fundamentals.
We would lean toward viewing the sector through a balance-sheet filter rather than a headline filter. The asymmetric setups will be those where operating growth, cash generation and per-share economics begin to converge. Until then, large percentage moves in thin or distressed securities should be treated as indicators of liquidity and sentiment, while the more durable valuation question remains whether each issuer can fund its strategy and convert scale into cash.